Cytomegalovirus & Epstein Barr Virus serostatus as a predictor of the long-term outcome of kidney transplantation

Nephrology

Volumn 18, Issue 12, 2013, Pages 813-819

  Le Page, Amelia K ^a,c   Mackie, Fiona E ^a,b   McTaggart, Steven J ^d   Kennedy, Sean E ^a,b,c  

^a SYDNEY CHILDREN'S HOSPITAL   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c ANZDATA Registry   (Australia)

^d Royal Children's and Mater Children's Hospitals   (Australia)

Author keywords

cytomegalovirus infection; Epstein Barr Virus infection; graft failure; kidney transplantation; patient survival

Indexed keywords

ADULT; AGE; ARTICLE; CANCER SURVIVAL; CYTOMEGALOVIRUS; EPSTEIN BARR VIRUS; FEMALE; GRAFT RECIPIENT; HUMAN; KIDNEY DONOR; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SMOKING; TREATMENT OUTCOME; BLOOD; GLOMERULUS FILTRATION RATE; GRAFT SURVIVAL; ISOLATION AND PURIFICATION; MIDDLE AGED;

VIRUS ANTIBODY;

ADULT; ANTIBODIES, VIRAL; CYTOMEGALOVIRUS; FEMALE; GLOMERULAR FILTRATION RATE; GRAFT SURVIVAL; HERPESVIRUS 4, HUMAN; HUMANS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 84888865862     PISSN: 13205358     EISSN: 14401797     Source Type: Journal    
DOI: 10.1111/nep.12149     Document Type: Article

References (18)

1. Crumpacker CS, Zhang J,. Cytomegalovirus. In:, Mandell G, Bennett J, Dolin R, (eds). Principles and Practices of Infectious Disease, 6th edn. New York: Churchill Livingston, 2009; 1971.
2. Walker RC, Paya CV, Marshall WF, et al. Pretransplantation seronegative Epstein-Barr virus status is the primary risk factor for posttransplantation lymphoproliferative disorder in adult heart, lung, and other solid organ transplantations. J. Heart Lung. Transplant. 1995; 14: 214-221.
3. Reischig T, Jindra P, Svecova M, Kormunda S, Opatrny K, Jr, Treska V,. The impact of cytomegalovirus disease and asymptomatic infection on acute renal allograft rejection. J. Clin. Virol. 2006; 36: 146-151.
4. Erdbruegger U, Scheffner I, Mengel M, et al. Impact of CMV infection on acute rejection and long-term renal allograft function: A systematic analysis in patients with protocol biopsies and indicated biopsies. Nephrol. Dial. Transplant. 2012; 27: 435-443.
5. Sagedal S, Hartmann A, Nordal KP, et al. Impact of early cytomegalovirus infection and disease on long-term recipient and kidney graft survival. Kidney Int. 2004; 66: 329-337.
6. Smith JM, Corey L, Bittner R, et al. Subclinical viremia increases risk for chronic allograft injury in pediatric renal transplantation. J. Am. Soc. Nephrol. 2010; 21 (9): 1579-1586.
7. Bamoulid J, Courivaud C, Coaquette A, et al. Subclinical Epstein-Barr virus viremia among adult renal transplant recipients: Incidence and consequences. Am. J. Transplant. 2013; 13 (3): 656-662.
8. Schnitzler MA, Lowell JA, Hardinger KL, Boxerman SB, Bailey TC, Brennan DC,. The association of cytomegalovirus sero-pairing with outcomes and costs following cadaveric renal transplantation prior to the introduction of oral ganciclovir CMV prophylaxis. Am. J. Transplant. 2003; 3 (4): 445-451.
9. Hodson EM, Craig JC, Strippoli GF, Webster AC,. Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients. Cochrane Database Syst. Rev. 2008; (2): CD003774.
10. Johnson RJ, Clatworthy MR, Birch R, Hammad A, Bradley JA,. CMV mismatch does not affect patient and graft survival in UK renal transplant recipients. Transplantation 2009; 88: 77-82.
11. Opelz G, Dohler B, Ruhenstroth A,. Cytomegalovirus prophylaxis and graft outcome in solid organ transplantation: A collaborative transplant study report. Am. J. Transplant. 2004; 4 (6): 928-936.
12. Kuo HT, Ye X, Sampaio MS, Reddy P, Bunnapradist S,. Cytomegalovirus serostatus pairing and deceased donor kidney transplant outcomes in adult recipients with antiviral prophylaxis. Transplantation 2010; 90: 1091-1098.
13. Schwartz GJ, Munoz A, Schneider MF, et al. New equations to estimate GFR in children with CKD. J. Am. Soc. Nephrol. 2009; 20: 629-637.
14. Caillard S, Porcher R, Provot F, et al. Post-transplantation lymphoproliferative disorder after kidney transplantation: Report of a nationwide French registry and the development of a new prognostic score. J. Clin. Oncol. 2013; 31 (10): 1302-1309.
15. Faull RJ, Hollett P, McDonald SP,. Lymphoproliferative disease after renal transplantation in Australia and New Zealand. Transplantation 2005; 80: 193-197.
16. ANZDATA. The 29th Annual Report. Adelaide: The ANZDATA Registry, 2006.
17. Luan FL, Samaniego M, Kommareddi M, Park JM, Ojo AO,. Choice of induction regimens on the risk of cytomegalovirus infection in donor-positive and recipient-negative kidney transplant recipients. Transpl. Infect. Dis. 2010; 12 (6): 473-479.
18. van Leeuwen MT, Grulich AE, Webster AC, et al. Immunosuppression and other risk factors for early and late non-Hodgkin lymphoma after kidney transplantation. Blood 2009; 114: 630-637.